Imperial Innovations leads £13.5m round for Precision Ocular

Imperial Innovation led the funding round with a £6.9m commitment, while pharma delivery company Consort Medical contributed £3.3m. Venture capital firm NeoMed Innovations and pharmaceutical manufacturer Hovione Scientia also joined the round.

The capital injection will support the development of the company's technologies and lead its programmes into human clinical studies.

Company
Founded in 2014 and headquartered in London, Precision Ocular operates in the retinal diseases segment.

The business develops specific treatments, which allow access to small spaces in the eye and provide drug distribution to the tissues specifically involved.

People
Imperial Innovations – Nigel Pitchford (chief investment officer).
Precision Ocular – Tom Cavanagh (CEO); Ron Yamamoto (chief scientific officer).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• UK / Ireland
• Venture
• Neomed Innovations
• United Kingdom